Circio (CRNA) Company presentation summary

Industry traction and financial highlights

• Secured three major industry deals in the past nine months, including M&A transactions valued at $1.5B and $2.4B, and a strategic deal up to $2.5B with leading pharma companies.

• Raised $65M in 2026 and listed on Euronext OSE under the ticker CRNA.

• Maintains a strong cash position of NOK 540 million, supporting R&D and business development through 2030.

Scientific leadership and platform innovation

• Pioneered the discovery of human circRNA, with foundational research cited over 8,200 times.

• Developed circVec, a proprietary circular RNA gene expression platform enabling up to 75x longer half-life and 60x higher protein expression compared to mRNA.

• circVec technology validated in heart, eye, and CNS, showing up to 60x increased gene expression in vivo.

Therapeutic applications and preclinical results

• circVec-AAV demonstrated 40x higher gene expression in heart and significant enhancement of therapeutic protein LAMP2B for Danon disease.

• Achieved up to 50x increased gene expression in ophthalmology and up to 60x in CNS across multiple delivery routes.

• circVec offers improved specificity, reduced off-target effects, and lower toxicity compared to mRNA-based vectors.